Gold nanoparticles approach to detect chondroitin sulphate and hyaluronic acid urothelial coating

Gabriella Guelfi1, Valentina Stefanetti1, Danilo Zampini1, Oommen P. Oommen2, Gabriele Brecchia1, Cecilia Dall’Aglio1, Rolando Arcelli1, Giovanni Cochetti3, Andrea Boni3 & Ettore Mearini3

This study investigated the location of hyaluronic acid (HA)- and chondroitin sulphate (CS)-coated gold nanoparticles in rabbit bladder and evaluated gene expression of CD44, RHAMM and ICAM-1 receptors involved in HA and CS transport into the cell. Gold nanoparticles were synthesised by reduction of gold salts with HA or CS to form HA-AuNPs and CS-AuNPs. Bladder samples were incubated with CS-AuNPs and HA-AuNPs or without glycosaminoglycans. Transmission electron microscopy, optic microscopy and scanning electron microscopy were used to determine the location of the synthesised AuNPs. Real-time PCR was used to analyse expression of urothelial cell receptors CD44, RHAMM, ICAM-1, after ex vivo administration of CS-AuNPs and HA-AuNPs. We showed that HA-AuNPs and CS-AuNPs were located in the cytoplasm and tight junctions of urothelial umbrella cells; this appearance was absent in untreated bladders. There were no significant differences in gene expression levels for CD44, RHAMM and ICAM-1 receptors in treated versus control bladder tissues. In conclusion, we clearly showed the presence of exogenous GAGs in the bladder surface and the tight junctions between umbrella cells, which is important in the regeneration pathway of the urothelium. The GAGs-AuNPs offer a promising approach to understanding the biophysical properties and imaging of urothelial tissue.

Bladder epithelium, also known as urothelium or transitional epithelium, is a highly specialised tissue that plays a key role in the defence of the bladder wall against various toxins. The urothelium is coated in a thick layer of glycosaminoglycans (GAGs) that acts as a non-specific anti-adherence factor and protects against infection1. This GAG layer is embedded in a network of proteins, forming the so-called glycocalyx2. Although the function of this layer is not yet fully understood, it has been suggested that it forms a physical barrier with hydro-repellent properties that protects epithelial cells against the irritative effects of urine components3. In fact, the high density of GAGs allows water molecules to form a surface impenetrable to many low molecular weight solutes4. There is strong evidence that an absence of GAGs is linked to loss of normal urothelial function. This loss of function results in “storage symptoms” such as frequency, which is an innate protective mechanism designed to minimise contact between urine and the damaged bladder wall5.

Hyaluronic acid (HA) and chondroitin sulphate (CS) are two naturally occurring GAGs abundantly present on bladder urothelium6. Many of the effects of HA are mediated through cell surface receptors, three of which have been molecularly characterised, namely cluster of differentiation 44 (CD44), hyaluronan-mediated motility receptor (HMMR), also known as RHAMM, and intercellular adhesion molecule-1 (ICAM-1)7. Although CD44 is the principal HA receptor, it also shows an affinity for CS8. The CD44 affinity of these polymers has resulted in the development of several nanoparticles for cancer targeting9 and bulk hydrogel scaffolds for tissue engineering10.

Administration of exogenous GAGs is widely accepted as therapy in various bladder disorders11,12. Intravesical instillation of HA and CS shows promise as a treatment for some bladder diseases, by promoting regeneration of GAG in the bladder urothelium13,14. However, data are lacking regarding the localisation of these molecules within the urothelium and the extent of their integration to cells or tissues.

1Department of Veterinary Medicine, University of Perugia, Perugia, PG, Italy. 2Faculty of Biomedical Sciences and Engineering & BioMediTech Institute, Bioengineering and Nanomedicine Lab, Tampere University of Technology, 33520, Tampere, Finland. 3Department of Surgical and Biomedical Sciences, Section of Urological, Andrological and Minimally invasive techniques, University of Perugia, Piazza Lucio Severi 1, 06132, Perugia, PG, Italy. Correspondence and requests for materials should be addressed to G.G. (email: gabriella.guelfi@unipg.it)
In order to improve the detectability of these molecules in tissue samples, we have engineered HA- and CS-coated gold nanoparticles (AuNPs)\(^\text{15}\), which have unique surface plasma resonance and optical properties\(^\text{16}\). In this study, we investigated the location of HA and CS after ex vivo incubation of rabbit bladder tissue with HA-AuNPs and CS-AuNPs to determine whether the benefits of HA and CS replacement therapy might be due to coating of the urothelium with GAGs. In addition, we evaluated relative gene expression of receptors involved in HA and CS transport into the cell (CD44, RHAMM and ICAM-1) in order to understand whether incubation with GAG nanoparticles modifies receptor expression.

**Materials and Methods**

**Ethics Statement.** The procedures involving the animals and their care were conducted in conformity with the national and international laws and policies. Animal protocols were reviewed and approved by the Animal Committee of the University of Perugia, Italy, and followed the guidelines for the care and use of animals at our institution (Comitato Universitario di Bioetica, permit number 129/2016-PR). All rabbits used for the study were provided by Centro Servizi per la ricerca pre-clinica (Perugia, Italy). All the animals were housed in each cage and fed with water and food ad libitum.

**Synthesis of CS and HA coated AuNPs.** CS 38 kDa and HA 1500 kDa were provided by IBSA, Italy. This particular molecular weight HA was chosen to best mimic in vivo conditions. Gold chloride and NaBH\(_4\) were purchased from Sigma-Aldrich. HA-AuNPs and CS-AuNPs were synthesised using the NaBH\(_4\) reduction method, as described by Tengdelius et al.\(^\text{17}\) with slight modifications. Briefly, gold chloride was dissolved in 10 mL of deionised water and refluxed for two hours then cooled to 60 °C. CS 30 mg (1 equivalent with respect to disaccharide units) was dissolved separately in 10 mL of deionised water. For the synthesis of HA-coated AuNPs, 24 mg (1 equivalent with respect to disaccharide units) of HA was used. The HA or CS solution was added to the gold solution (kept at 60 °C) and NaBH\(_4\) (4.56 mg, 0.12 mmol, 2 equivalents) was added. The reaction was left to progress for 8 hours at 60 °C and the formation of NP was observed immediately as the colour changed to deep violet. Therefore, the CS-AuNP and HA-AuNP solutions were loaded into a dialysis bag (MWCO 3500), dialysed against deionised water (4 × 2 L) for 48 h and lyophilsed to obtain 30 mg of CS-AuNPs or 25 mg of HA-AuNPs.

The compounds were stored at room temperature and before use were re-suspended in water at a final concentration of 1 mg/mL.

**Synthesis of BSA-AuNP.** BSA-AuNP used as a control in the study was obtained by incubating commercially available citrate coated gold nanoparticles (40 nm, from EY Laboratories, Inc.) with BSA following the reported protocol\(^\text{18}\). The concentration of BSA used for coating was same as the two GAGs used to synthesize HA and CS AuNPs.

**Nanoparticle characterisation.** CS-AuNPs and HA-AuNPs were monitored using spectrophotometric measurements (Evolution 201 UV VIS; Thermo Fisher). Transmission electron microscopy (TEM; Philips EM 208 equipped with a digital camera) measurements were made from samples prepared by placing drops of the gold NP dispersions on carbon-coated TEM copper grids (Società Italiana Chimici-Roma); mixtures were allowed to dry for 1 minute then excess solution was removed using blotting paper. Dynamic light scattering (DLS) measurements were carried out using Malvern’s Zetasizer Nano ZS instrument.

**Animals and tissue preparation.** Eighteen 8-week-old healthy New Zealand female White rabbits (≥1500 ± 200 g) were used in the study. Animals were sedated with 0.2 mg/kg medetomidine (Medetor; VirbacSrl) and 10 mg/kg intramuscular ketamine (Inoketam; VirbacSrl) and anaesthetised with 5% isofluorane. Rabbits were euthanised (weighing 5–6 g) and washed extensively with sterile phosphate-buffered saline (PBS) supplemented with penicillin 200 µg/mL, streptomycin 200 µg/mL, and amphotericin-B 12.5 µg/mL (Sigma-Aldrich; St. Louis, USA) to remove debris. Tissue was then placed in 5 mL of Dulbecco’s Modified Eagle Medium (DMEM, Gibco; Gaithersburg, USA), 10% foetal bovine serum (Gibco, Gaithersburg, USA), penicillin 200 U/mL, streptomycin 200 mg/mL, and amphotericin-B 12.5 µg/mL.

**GAGs treatment.** Twelve rabbit bladder sections (weighing 0.7 to 0.9 g) were incubated with 500 µL of CS-AuNPs (1 mg/mL) and 500 µL of HA-AuNPs (1 mg/mL) at 37 °C for 60 minutes; the other six samples received the same treatment but were incubated with colloidal gold solution adsorbed with bovine serum albumin instead of GAGs (BSA-AuNPs; control). The 60-minute incubation time was adopted as during this time, no significant necrosis or cell degeneration as observed.

**Sample preparation for microscopy.** Bladder samples for optical microscopy were fixed by immersion in 2.5% glutaraldehyde in 0.1 M PBS at room temperature for 24 hours. Then the tissue samples were dehydrated through a graded series of ethanol, cleared in xylene and embedded in paraffin. Sections were processed for a better identification of the bladder epithelium using haematoxylin-eosin (HE) staining (Sigma-Aldrich, St. Louis, Mo, USA).

For scanning electron microscopy (SEM; Philips XL 30 resolution: 2.0 nm at 30 kV and 10 mbar water vapour), small bladder samples were fixed in 2.5% glutaraldehyde in distilled water for 2 hours at room temperature. Samples were washed in distilled water for 20 minutes, and dehydrated through ascending grades ethanol, according to the critical point drier method. Dried specimens were mounted on stubs with silver paste and sputtered with gold (200–250 nm) by cathode atomisation under vacuum.

For TEM, small samples of bladder tissue were placed in 2.5% glutaraldehyde added to 0.1 M PBS, pH 7.3, for 3 hours at room temperature. After rinsing twice in PBS, the specimens were post-fixed in 1% buffered osmium.
tetroxide at pH 7.2 for 3 hours at 4 °C. Samples were then dehydrated, pre-infiltrated and embedded in Epon 812. Semi-thin sections (1 µm) were obtained and stained with methylene blue and Azur blue II19 and examined under a light microscope to identify the best specimens. Ultrathin sections were mounted on 200-mesh copper grids, stained with uranyl acetate and lead citrate20.

**Evaluation of receptor RNA expression.** RNA was extracted from 5 µm paraffin-embedded bladder sections adjacent to that observed using optical microscopy. Extraction was performed with a commercial kit (RecoverAll Total Nucleic Acid Isolation Kit; Ambion, Austin, USA) following the manufacturer’s instructions. Total RNA was quantified with a fluorometer (Qubit 2.0, Invitrogen, Carlsbad, USA). About 20 ng of total RNA were reverse transcribed (RT) in 20 µL of iSCRIPT®cDNA (BioRad; Hercules, USA) using random hexamers. No-RT controls were included to check for genomic DNA contamination.

Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was carried out with 5 µL of a ten-fold diluted cDNA in a final volume of 25 µL using 10 µL of SsoFast™ EvaGreen® Supermix (BioRad; Hercules, USA). Primers for CD44, RHAMM and ICAM-1 were commercially purchased (PrimePCRSyberGreen Assay, Bio-Rad; Hercules, CA, USA).

All PCR reactions (Bio-Rad iCycler Real-Time PCR) had an initial incubation at 95 °C for 15 minutes, followed by 45 cycles at 95 °C for 15 seconds and 60 °C for 1 minute, during which fluorescence data were collected. Each sample was run in triplicate and the results were averaged. Sample amplification fidelity was verified by agarose gel electrophoresis. 18 S rRNA was used as an endogenous control to normalise variations in the amount of starting RNA samples as previously reported21. For each PCR run, no template controls and no-RT controls were included in order to ascertain the absence of gDNA.

The 2−ΔΔCt method was used to calculate the relative expression of the target genes as follows22:

\[ \frac{(C_{\text{target}} - C_{18S}) - (C_{\text{control}} - C_{18S})}{2} \]

**Statistical analysis.** Results are presented as mean ± standard error (SE). Statistical comparisons between groups were performed using unpaired t-test. Significance was set at p ≤ 0.05. All analyses were performed in GraphPad Prism version 6.00.

**Results**

**GAGs-AuNPs evaluation.** GAGs-AuNPs displayed a UV-Vis analysis at λmax 546 nm (HA) and 520 (CS) single surface plasma resonance, suggesting formation of spherical morphology (Fig. 1).

DLS analysis indicated that for HA-AuNPs 89% nanoparticles had a size of 98 ± 18 nm, while a zeta potential (Zp) = −36.5 ± 5 mV, and for CS-AuNPs 99.4% nanoparticles had a size of 58 ± 12, with a Zp = −23.5 ± 4 mV. On the contrary, TEM analysis indicated a 40 ± 1.5 nm and 19 ± 0.6 nm radius, for HA-AuNPs and CS-AuNPs respectively, as Fig. 2 shows.

The higher hydrodynamic size of the nanoparticles as determined by DLS are attributed to the hydration of GAG coat, which is not discernible in the TEM measurements.

**Microscopy evaluations.** After ex vivo incubation, SEM observations showed the vast majority of epithelial cells with a scalloped luminal face being covered by some ridges of GAGs-AuNPs (Fig. 3). This appearance was absent in untreated bladders (Fig. 4).

TEM analysis showed some particles of GAGs-AuNPs behind plasma membranes of apex line cells of the bladder epithelium (Fig. 5). In particular, some GAGs-AuNPs were evident in the cytoplasm (Figs 6 and 7), suggesting that nanoparticles can enter inside the cells, overcoming the plasma membrane barrier, and localise on the membranes of cytoplasmic organelles.

**PCR assessment.** Single peaks in the melting curves confirmed the uniqueness of PCR products. There were no statistically significant differences in receptor gene expression in bladders incubated with HA-AuNP and CS-AuNP compared with control. The ICAM-1 gene showed the highest mRNA expression level in treated group
Figure 2. Transition electron microscopy (TEM) image showed both GAGs-AuNPs (19 to 40 nm), re-dispersed in water and deposited in the form of films onto carbon-coated TEM grids.

Figure 3. Scanning electron microscopy (SEM) image of treated bladder epithelium showing GAGs-AuNPs (arrow) linked to the plasma membranes of epithelial cells.

Figure 4. Scanning electron microscopy (SEM) image of untreated (control) bladder epithelium showing an absence of any visible aggregates.
(1.83 ± 1.23) vs control (1.82 ± 0.56) while CD44 and HMMR gene expression in treated samples (0.74 ± 0.28 and 0.15 ± 0.05) were lower than those in control samples (0.56 ± 0.10 and 0.06 ± 0.02) (Fig. 8).

**Discussion**

This study showed the presence of exogenous GAGs in bladder umbrella cells after *ex vivo* incubation of samples with gold nanoparticles containing CS and HA. No change in GAG receptor expression levels was detected in treated bladders.

The rabbit bladder is a good model for investigating the physiological, histological, and biochemical properties of the functioning human bladder. Similarities include similar receptor distribution in the urinary tract and comparable pharmacological responses to a wide variety of agents. The use of rabbit bladders offers several advantages, including availability of samples and transport of bladder tissue, and fewer ethical issues problems compared with the use of bladders from other species (e.g. dogs, pigs or humans).

We investigated the location of HA- and CS-coated gold nanoparticles in rabbit bladder tissue in order to demonstrate that the mechanism of action of GAGs replacement therapy is presumed to be due to a real coating of the bladder surface to replace physiological HA and CS lost as a result of disease. AuNPs are emerging as a very useful tool due to their unique electronic, optical, and catalytic properties, with simple synthesis, good stability.
and chemical inertness compared with other nanocarriers\textsuperscript{25}. GAGs molecules with the sulphated polyanionic structure stabilise AuNPs in aqueous solution, thus improving biocompatibility of the metal\textsuperscript{15}.

A GAG layer covers the umbrella cells and contributes to urothelial barrier function, also reducing the adhesion of many urinary bacterial pathogens. Furthermore, several events originating from intravesical GAG injury may result in chronic damage to the bladder epithelium and prevent healing due to direct contact of abnormal urinary constituents with the subepithelial layer. Prompt restoration of the GAG layer to prevent the inflammatory cycle is a rationale underlying treatment of chronic cystitis and painful bladder syndrome/interstitial cystitis\textsuperscript{26}. “GAG replacement therapy” is effective in many patients, as shown in several models of urothelial damage, showing strong surface binding\textsuperscript{11}. Another treatment option, based on endocavital GAG replenishment therapy has been shown to improve urinary irritative symptoms secondary to pelvic radiation therapy (RT)\textsuperscript{27}, and to have potential as prophylactic therapy in this setting\textsuperscript{28}. RT stimulates a neuroinflammatory cascade with activation

Figure 7. Transition electron microscopy (TEM) image showing GAGs-AuNPs linked to the plasma membrane of epithelial cells with some particles localised in the cytoplasm nearest to cellular membranous structures.

Figure 8. Light microphotograph (A) with haematoxylin and eosin (HE) stain showing histologic evaluation of rabbit bladder (Top to base: umbrella, intermediate and basal cells; arrows show the typical “dome-shaped” apical cells). Normalized expression value $2^{-\Delta\Delta Ct}$ (mean ± standard error) (B) of CD44, RHAMM and ICAM-1 in bladder tissues incubated with HA-AuNP and CS-AuNP (left box for each type of receptor) and control bladder tissues incubated with BSA-AuNPs solution (dashed line).
of mast cell and release of histamine that could be inhibited by HA, while CS promotes regeneration of the AG layer.32

This study clearly showed the presence of exogenous GAGs in tight junctions and in the cytoplasm of umbrella cells. This is particularly important if we consider the regeneration pathway of the urothelium. In fact, within a few days of urothelial damage, tight junctions begin to develop between intermediate cells, increasing the water-tightness of the new layer. In this sense, the early or prophylactic administration of exogenous GAGs could play an important role in the rapid restoration of the urothelial impermeability.29 In particular, the tight junction plays a leading role in the establishment of the transepithelial resistances, thus blocking ion flux within the epithelium. We also showed that HA and CS were able to penetrate into umbrella cells, which prompted us to evaluate intracellular signal transduction pathways using real-time PCR. Most of the effects of HA are mediated through CD44, RHAMM, and ICAM-1. Binding of the HA ligand to its receptors can direct cell trafficking during physiological and pathological events.30 Our aim was also to demonstrate that the entry of HA and CS into umbrella cells is not associated with an increase in expression of CD44, RHAMM, and ICAM-1, and this was indeed the case. Southgate and colleagues reported CD44 expression in the basal layer of normal human urothelium that progressed from the basal to the superficial layer, where expression was lost. Similar CD44 expression profiling has been portrayed in rabbit bladder.32 Further studies are warranted to facilitate understanding of the role of CD44, RHAMM, and ICAM-1 in the transitional epithelium.

A limitation of this research is that the microscopy analysis of GAG-AuNPs has only a qualitative value. As a result, we can only confirm the presence (not the quality) of GAGs–AuNPs on the urothelial mucosa. In addition, our aim was to investigate receptors on the surface of the urothelial cells and therefore we do not have information on the mechanism of uptake of GAG-AuNPs.

Conclusions

This study clearly shows not only the presence of exogenous GAGs in the bladder surface but also in the tight junctions between umbrella cells, which is important in the regeneration pathway of the urothelium. Based on our findings, the entry of GAGs into urothelial cells does not seem to alter their receptor gene expression. The GAGs–AuNPs offer a promising approach to understanding the biophysical properties and imaging of urothelial tissue. In future, we will validate these results in an in vivo rabbit model and evaluate the administration of GAGs as a polymer and as AuNPs in an experimental model of cystitis, in order to study GAG-related molecular processes.

References

1. Damiano, R. & Cicione, A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol 3, 223–232 (2011).
2. Wilson, C. B. et al. Extracellular matrix and integrin composition of the normal bladder wall. World J Urol 14(Suppl 1), S30–37 (1996).
3. Poggi, M. M., Johnstone, P. A. & Conner, R. J. Glycosaminoglycan content of human bladders. a method of analysis using cold-cup biopsies. Urol Oncol 5, 234–237 (2000).
4. Hurst, B. E. & Zebrowski, R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol 152, 1641–1645 (1994).
5. Parsons, C. L. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 69, 9–16 (2007).
6. Porrn, D. et al. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J 23, 1193–1199 (2012).
7. Entwistle, J., Hall, C. L. & Turley, E. A. HA receptore regulators of signalling to the cytoskeleton. J Cell Biochem 61, 569–577 (1996).
8. Rudcki, Z. & Jothy, S. CD44 and the adhesion of neoplastic cells. Mol Pathol 50, 57–71 (1997).
9. Osmmen, O. P. et al. Multifunctional hyaluronic acid and chondroitin sulfate nanoparticles: impact of glycosaminoglycan presentation on receptor mediated cellular uptake and immune activation. ACS Appl Mater Interfaces 8, 20614–20624 (2016).
10. Osmmen, O. P. et al. Smart design of stable extracellular matrix mimetic hydrogel: synthesis, characterization, and in vitro and in vivo evaluation for tissue engineering. Adv Funct Mater 23, 1273–1280 (2013).
11. Lazzari, M. et al. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Ther Adv Urol 8, 91–99 (2016).
12. Fall, M. et al. EAU guidelines on chronic pelvic pain. Eur Urol 57, 35–48 (2010).
13. De Vita, D. & Giordano, S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J 23, 1707–1713 (2012).
14. Cianci, O. et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case–control study. BJM Open 6, e009669 (2016).
15. Li, W. et al. Facile synthesis of chondroitin sulfate-stabilized gold nanoparticles. Mater Chem Phys 125, 518 (2011).
16. Mandal, S., Phadare, S. & Sastry, M. Interacing biology with nanoparticles. Curr Appl Phys 5, 118–127 (2005).
17. Tengdelius, M. et al. Synthesis and anticancer properties of fucoidian-mimetic glycopolymer coated gold nanoparticles. Chem Commun Camb Engl 51, 8532–8535 (2015).
18. Brewer, S. H. et al. Probing BSA binding to citrate-coated gold nanoparticles and surfaces. Langmuir 21, 9303–9307 (2005).
19. Leeo, C. R. & Leeson, T. S. Staining methods for sections of epon-embedded tissues for light microscopy. Can J Can J Zool 48, 189–191 (1970).
20. Venable, J. H. & Coggeshall, R. A simplified lead citrate stain for use in electron microscopy. J Cell Biol 25, 407–408 (1965).
21. Peng, X. et al. Selection of suitable reference genes for normalization of quantitative real-time PCR in cartilage tissue injury and repair in rabbits. Int J Mol Sci 13, 14344–14355 (2012).
22. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) Method. Methods 25, 402–408 (2001).
23. Balascheghin, K. T. et al. Experimental model of bladder instability in rabbits. Int Braz J Urol 29, 62–67 (2003).
24. Levin, R. M. et al. Rabbit as a model of urinary bladder function. Neurourol Urodyn 13, 119–135 (1994).
25. Muddinetti, O. S., Ghosh, B. & Biswas, S. Current trends in using polymer coated gold nanoparticles for cancer therapy. Int J Pharm 484, 252–267 (2015).
26. Han, X. M. et al. The effects of intravesical therapy with hyaluronic acid for painful bladder syndrome: Preliminary Chinese experience and systematic review. Taiwan J Obstet Gynecol 54, 240–247 (2015).
27. Gacci, M. et al. Bladder instillation therapy with hyaluronic acid and chondroitin sulfate improves symptoms of post radiation cystitis: prospective pilot study. *Clin Genitourin Cancer* **14**, 444–449 (2016).
28. Hazewinkel, M. H. et al. Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies. *Int Urogynecol J* **22**, 725–730 (2011).
29. Khandelwal, P., Abraham, S. N. & Apodaca, G. Cell biology and physiology of the uroepithelium. *Am J Physiol Renal Physiol* **297**, F1477–1501 (2009).
30. Entwistle, J., Hall, C. L. & Turley, E. A. HA receptors: regulators of signalling to the cytoskeleton. *J Cell Biochem* **61**, 569–577 (1996).
31. Southgate, J. et al. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder carcinoma cell lines. *Int J Cancer* **62**, 449–456 (1995).
32. Arafat, H. A., Wein, A. J. & Chacko, S. Osteopontin gene expression and immunolocalization in the rabbit urinary tract. *J Urol* **167**, 746–752 (2002).

**Acknowledgements**
We gratefully acknowledge IBSA Farmaceutici Italia S.r.L, whose long-standing commitment to improving public health through community-based participatory research has made important contributions. The authors would like to thank Dr. Anna Beatrice Casano and Dr. Giovanni Angeli of Department of Veterinary Medicine, University of Perugia (Italy) for their skilful technical assistance. Medical writing assistance was provided by Nicola Ryan, an independent medical writer on behalf of Springer Healthcare Communications, funded by IBSA Farmaceutici Italia S.r.L. This project was funded by IBSA Farmaceutici Italia S.r.L. The sponsor had no role in study design, collection, analysis and interpretation of data, or in writing the manuscript and the decision to submit for publication.

**Author Contributions**
G.G., D.Z., O.P.O. and C.D. made substantial contributions to conception and design; acquisition of data was undertaken by G.G., O.P.O., G.C., R.A., A.B. and E.M.; data analysis and interpretation was undertaken by G.G., V.S. and C.D.; the manuscript was drafted by G.G., V.S. and A.B., and all authors critically revised the manuscript for important intellectual content. D.Z. performed the statistical analysis and E.M. obtained funding. Administrative, technical or material support was provided by G.G. and A.B., while G.C., A.B. and E.M. provided supervision. G.B. was the expert in laboratory animal medicine.

**Additional Information**
**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2017